BioVie’s bezisterim improves fatigue in more severely affected Long COVID patients in Phase 2 trial
BIVI•BioVie presented Phase 2 ADDRESS-LC results for bezisterim, a 12-week placebo-controlled trial of 203 patients with Long COVID. Patients with greater baseline symptom severity showed statistically significant improvements in fatigue, post-exertional malaise or cognition.
1. Trial findings
BioVie presented Phase 2 ADDRESS-LC results for bezisterim at the American Neurological Association annual meeting in San Diego. The placebo-controlled trial enrolled 203 patients for 12 weeks; overall results showed a trend toward improvement across most efficacy measures. Patients with greater baseline symptom severity showed the strongest benefits, including statistically significant improvements in fatigue, post-exertional malaise or cognition. Safety and tolerability were comparable to placebo, with no serious treatment-emergent adverse events in the bezisterim group. The findings could guide a confirmatory Phase 3 study, while biomarker results remain pending analysis for presentation at a future medical meeting.
